Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Recurrence of PBC and PSC after LT is increasingly well described in large cohorts and long-term follow-up. In this setting, the preventive effect of ursodeoxycholic acid on PBC recurrence, as well as the deleterious role of tacrolimus are now well documented. In addition, the significant negative impact of recurrent PBC on survival after LT has recently been demonstrated. With respect to rejection-associated biliary injury, a growing body of evidence is emerging on the role of anti-HLA antibody-mediated rejection. SUMMARY: Immune-mediated cholangiopathies occurring after LT can be divided in two main nosologic groups: biliary lesions due to recurrence of PBC or PSC, or in the context of rejection, either acute or chronic, T-cell- or antibody-mediated. GVHD is very rare. Final diagnosis is strongly based on clinical context (indication for LT, delay since transplantation, biological abnormalities, imaging) but also and to an even greater extent on biopsy of liver graft. Clinico-pathological discussions are recommended, hearing in mind that diseases can be intertwined.
|
Authors | Jérôme Dumortier, Filomena Conti, Jean-Yves Scoazec |
Journal | Current opinion in gastroenterology
(Curr Opin Gastroenterol)
Vol. 38
Issue 2
Pg. 98-103
(03 01 2022)
ISSN: 1531-7056 [Electronic] United States |
PMID | 35098931
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
Topics |
- Cholangitis, Sclerosing
(complications)
- End Stage Liver Disease
- Graft vs Host Disease
- Humans
- Liver Cirrhosis, Biliary
- Liver Transplantation
(adverse effects)
- Neoplasm Recurrence, Local
- Recurrence
|